Host: Neilanjan Nandi, MD
Guest: Russell D. Cohen, MD, FACG, AGAF
New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More